AL-DAWAA MEDICAL SERVICES COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92 SAR | -2.13% |
|
-3.26% | -13.04% |
| 30/04 | Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue | MT |
| 30/04 | Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,112 | 8,993 | 7,990 | - | - |
| Enterprise Value (EV) 1 | 6,112 | 11,093 | 9,436 | 8,926 | 8,848 |
| P/E ratio | 20 x | 27.3 x | 19.6 x | 16.5 x | 14.9 x |
| Yield | - | - | 3.15% | 3.57% | 4.35% |
| Capitalization / Revenue | 1.14 x | 1.57 x | 1.28 x | 1.21 x | 1.13 x |
| EV / Revenue | 1.14 x | 1.93 x | 1.52 x | 1.35 x | 1.25 x |
| EV / EBITDA | 8.45 x | 13.4 x | 10.3 x | 9.12 x | 8.56 x |
| EV / FCF | - | 21.8 x | 15.8 x | 17.9 x | 18.1 x |
| FCF Yield | - | 4.59% | 6.35% | 5.58% | 5.54% |
| Price to Book | - | 6.85 x | 5.61 x | 5 x | 4.61 x |
| Nbr of stocks (in thousands) | 85,000 | 85,000 | 85,000 | - | - |
| Reference price 2 | 71.90 | 105.8 | 92.00 | 92.00 | 92.00 |
| Announcement Date | 26/03/23 | 18/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 5,034 | 5,372 | 5,741 | 6,228 | 6,619 | 7,085 |
| EBITDA 1 | - | 600.1 | 723.6 | 830.4 | 917.2 | 979.2 | 1,033 |
| EBIT 1 | - | 266.2 | 369 | 466.7 | 536.6 | 571.6 | 623.2 |
| Operating Margin | - | 5.29% | 6.87% | 8.13% | 8.62% | 8.64% | 8.8% |
| Earnings before Tax (EBT) 1 | - | 246 | - | 342.4 | 412 | 500.3 | 545.5 |
| Net income 1 | 246.4 | 239.1 | 305.4 | 329.2 | 399.7 | 474.7 | 524.6 |
| Net margin | - | 4.75% | 5.69% | 5.73% | 6.42% | 7.17% | 7.41% |
| EPS 2 | 1,232 | 2.810 | 3.590 | 3.870 | 4.702 | 5.581 | 6.170 |
| Free Cash Flow 1 | - | 291.7 | - | 508.9 | 599 | 498 | 490 |
| FCF margin | - | 5.79% | - | 8.86% | 9.62% | 7.52% | 6.92% |
| FCF Conversion (EBITDA) | - | 48.6% | - | 61.28% | 65.3% | 50.86% | 47.42% |
| FCF Conversion (Net income) | - | 121.96% | - | 154.58% | 149.85% | 104.92% | 93.4% |
| Dividend per Share 2 | - | 4.130 | - | - | 2.898 | 3.285 | 4.001 |
| Announcement Date | 22/12/21 | 31/03/22 | 26/03/23 | 18/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | 1,439 | 1,458 | 1,516 |
| EBITDA | - | - | 215.6 | - |
| EBIT 1 | - | 102 | 127.7 | 130.5 |
| Operating Margin | - | 7.09% | 8.76% | 8.61% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | 89.33 | 71.28 | 92.35 | 95.33 |
| Net margin | - | 4.95% | 6.33% | 6.29% |
| EPS | 1.050 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 03/08/23 | 02/11/23 | 18/03/24 | 29/04/24 |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 2,100 | 1,446 | 936 | 858 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 2.528 x | 1.577 x | 0.9561 x | 0.8304 x |
| Free Cash Flow 1 | - | 292 | - | 509 | 599 | 498 | 490 |
| ROE (net income / shareholders' equity) | - | 22.8% | - | 27.3% | 29.4% | 30.7% | 31% |
| ROA (Net income/ Total Assets) | - | 6.31% | - | 7.15% | 8.32% | 9.49% | 9.49% |
| Assets 1 | - | 3,788 | - | 4,602 | 4,802 | 5,004 | 5,528 |
| Book Value Per Share 2 | - | 11.60 | - | 15.40 | 16.40 | 18.40 | 20.00 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 378 | - | 217 | 223 | 235 | 225 |
| Capex / Sales | - | 7.52% | - | 3.78% | 3.58% | 3.55% | 3.18% |
| Announcement Date | 22/12/21 | 31/03/22 | 26/03/23 | 18/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
92
SAR
Average target price
114.2
SAR
Spread / Average Target
+24.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.04% | 2.13B | |
| -34.16% | 14.83B | |
| -24.55% | 12.04B | |
| -25.24% | 6.52B | |
| +14.96% | 6.44B | |
| -8.01% | 6.15B | |
| -2.48% | 4.64B | |
| +60.00% | 4.62B | |
| -8.10% | 3.93B | |
| -11.16% | 3.49B |
- Stock Market
- Equities
- 4163 Stock
- Financials Al-Dawaa Medical Services Company
